Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China
· Delayed Price · Currency is CNY 3.250
+0.030 (0.93%)
Apr 29, 2026, 3:04 PM CST
SHE:002589 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Market Capitalization | 4,824 | 4,779 | 4,444 | 4,920 | 6,165 | 5,881 | Upgrade
|
| Market Cap Growth | 11.54% | 7.54% | -9.67% | -20.19% | 4.83% | -24.86% | Upgrade
|
| Enterprise Value | 4,941 | 6,475 | 7,022 | 3,501 | 7,785 | 11,382 | Upgrade
|
| Last Close Price | 3.25 | 3.22 | 2.97 | 3.24 | 4.08 | 3.89 | Upgrade
|
| PE Ratio | 336.05 | 297.39 | 215.52 | 242.17 | - | 44.83 | Upgrade
|
| Forward PE | - | 8.02 | 8.02 | 8.02 | 8.02 | 8.45 | Upgrade
|
| PS Ratio | 0.67 | 0.66 | 0.56 | 0.61 | 0.50 | 0.28 | Upgrade
|
| PB Ratio | 0.89 | 0.88 | 0.78 | 0.87 | 1.07 | 0.61 | Upgrade
|
| P/TBV Ratio | 1.03 | 1.03 | 0.90 | 1.04 | 1.33 | 0.91 | Upgrade
|
| P/FCF Ratio | - | - | 90.86 | - | 17.51 | - | Upgrade
|
| P/OCF Ratio | - | 347.35 | 27.70 | 59.67 | 11.79 | 13.28 | Upgrade
|
| PEG Ratio | - | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | Upgrade
|
| EV/Sales Ratio | 0.68 | 0.89 | 0.88 | 0.44 | 0.63 | 0.54 | Upgrade
|
| EV/EBITDA Ratio | 16.95 | 26.43 | 36.51 | 26.75 | 46.91 | 10.22 | Upgrade
|
| EV/EBIT Ratio | 53.49 | 94.99 | 228.27 | - | - | 13.99 | Upgrade
|
| EV/FCF Ratio | -121.79 | - | 143.54 | - | 22.11 | - | Upgrade
|
| Debt / Equity Ratio | 0.93 | 0.85 | 1.16 | 1.21 | 0.70 | 0.47 | Upgrade
|
| Debt / EBITDA Ratio | 17.28 | 17.47 | 33.65 | 50.40 | 22.86 | 4.01 | Upgrade
|
| Debt / FCF Ratio | - | - | 134.50 | - | 11.37 | - | Upgrade
|
| Net Debt / Equity Ratio | 0.00 | 0.16 | 0.28 | 0.31 | -0.23 | 0.00 | Upgrade
|
| Net Debt / EBITDA Ratio | -0.04 | 3.51 | 8.29 | 13.47 | -8.05 | -0.03 | Upgrade
|
| Net Debt / FCF Ratio | 0.27 | -65.87 | 32.61 | -8.17 | -3.79 | 1.92 | Upgrade
|
| Asset Turnover | 0.46 | 0.48 | 0.49 | 0.46 | 0.55 | 0.72 | Upgrade
|
| Inventory Turnover | 9.68 | 8.99 | 7.66 | 6.96 | 7.07 | 6.92 | Upgrade
|
| Quick Ratio | 1.01 | 1.00 | 1.03 | 0.96 | 0.93 | 1.08 | Upgrade
|
| Current Ratio | 1.10 | 1.09 | 1.12 | 1.07 | 1.03 | 1.25 | Upgrade
|
| Return on Equity (ROE) | 0.77% | 0.79% | 0.72% | 0.56% | -22.52% | 3.78% | Upgrade
|
| Return on Assets (ROA) | 0.37% | 0.28% | 0.12% | -0.30% | -0.30% | 1.74% | Upgrade
|
| Return on Invested Capital (ROIC) | 1.58% | 1.00% | 0.41% | -1.43% | -1.54% | 5.47% | Upgrade
|
| Return on Capital Employed (ROCE) | 1.60% | 1.20% | 0.50% | -1.40% | -1.90% | 8.20% | Upgrade
|
| Earnings Yield | 0.30% | 0.34% | 0.46% | 0.41% | -29.70% | 2.23% | Upgrade
|
| FCF Yield | -0.84% | -0.27% | 1.10% | -4.39% | 5.71% | -0.31% | Upgrade
|
| Dividend Yield | 0.06% | - | 0.37% | 0.40% | - | 0.23% | Upgrade
|
| Payout Ratio | 1245.37% | 1085.79% | 963.58% | 992.70% | - | 241.13% | Upgrade
|
| Buyback Yield / Dilution | -30.32% | -6.77% | -0.01% | -1.93% | -1.30% | -0.40% | Upgrade
|
| Total Shareholder Return | -30.26% | -6.77% | 0.36% | -1.53% | -1.30% | -0.17% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.